Sharon Townson - 23 Jun 2026 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Reporting relationship: Chief Scientific Officer
Issuer ticker: GLUE
Reported as of: 23 Jun 2026
Net transaction value: -$60,000
SEC form: 4
Accepted by SEC: 25 Jun 2026, 16:05:03 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Phil Nickson, Attorney-in-Fact

Key filing fact

Sharon Townson filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 25 Jun 2026.

Key facts

This page summarizes Sharon Townson's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Jun 2026, 16:05.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: -$60,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001855689 Primary reporting owner

Townson Sharon

Relationship: Chief Scientific Officer
Address: MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON
Signature: /s/ Phil Nickson, Attorney-in-Fact
Signature date: 25 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GLUE transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,000
Change %: +4.4%
Price: $6.14^*
Shares after: 70,845
Date: 23 Jun 2026
Ownership: Direct
Footnotes: F1

GLUE transaction

Common Stock

Sale

Transaction value: $60,000
Shares: -3,000
Change %: -4.2%
Price: $20.00
Shares after: 67,845
Date: 23 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GLUE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -3,000
Change %: -1.5%
Price: $0.000000^*
Shares after: 203,290
Date: 23 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price: $6.14
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

Footnote F2

The shares underlying this option are fully vested and exercisable.